Myocardial repolarization dispersion and late gadolinium enhancement in patients with hypertrophic cardiomyopathy

Circulation Journal

Volumn 78, Issue 5, 2014, Pages 1216-1223

  Magrì, Damiano ^a   De Cecco, Carlo Nicola ^a,c   Piccirillo, Gianfranco ^a   Mastromarino, Vittoria ^a   Serdoz, Andrea ^a   Muscogiuri, Giuseppe ^a   Ricotta, Agnese ^a   Gregori, Mario ^a   Marino, Laura ^a   Cauti, Filippo Maria ^a   Pagannone, Erika ^a   Musumeci, Maria Beatrice ^a   Maruotti, Antonello ^b,d   Autore, Camillo ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cardiac magnetic resonance imaging; Hypertrophic cardiomyopathy; QT variability; Ventricular arrhythmia

Indexed keywords

GADOLINIUM;

ADULT; AGE; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; COMPARATIVE STUDY; FEMALE; HEART HYPERTROPHY; HEART LEFT ATRIAL VOLUME; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HEART VOLUME; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; QT DISPERSION; RISK FACTOR; SUDDEN CARDIAC DEATH;

EID: 84899655159     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1423     Document Type: Article

References (49)

1. Maron BJ. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. Circ J 2010; 74: 2271-2282.
2. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58: e212-e260, doi:10.1016/j.jacc.2011.06.011.
3. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, et al. Implantable cardioverter defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298: 405-412.
4. Cannon RO III. Assessing risk in hypertrophic cardiomyopathy. N Engl J Med 2003; 349: 1016-1018.
5. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. J Am Coll Cardiol 2000; 36: 2212-2218.
6. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, et al. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral-based patient population. Circulation 2000; 102: 858-864.
7. Maron BJ, Maron MS, Lesser JR, Hauser RG, Haas TS, Harrigan CJ, et al. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol 2008; 101: 544-547.
8. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: Pathologic evidence of myocardial ischemia. Hum Pathol 2000; 31: 988-998.
9. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000; 35: 36-44.
10. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45: 697-704.
11. Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008; 1: 184-191.
12. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008; 51: 1369-1374.
13. Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010; 3: 51-58.
14. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2012; 14: 13.
15. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012; 5: 370-377.
16. Atiga WL, Calkins H, Lawrence JH, Tomaselli GF, Smith JM, Berger RD. Beat-to-beat repolarization lability identifies patients at risk for sudden cardiac death. J Cardiovasc Electrophysiol 1998; 9: 899-908.
17. Haigney MC, Zareba W, Gentlesk PJ, Goldstein RE, Illovsky M, McNitt S, et al. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial [MADIT] II. J Am Coll Cardiol 2004; 44: 1481-1487.
18. Piccirillo G, Magrì D, Matera S, Magnanti M, Torrini A, Pasquazzi E, et al. QT variability strongly predicts sudden cardiac death in asymptomatic subjects with mild or moderate left ventricular systolic dysfunction: A prospective study. Eur Heart J 2007; 28: 1344-1350.
19. Piccirillo G, Magrì D, Pappadà MA, Maruotti A, Ogawa M, Han S, et al. Autonomic nerve activity and the short term variability of Tpeak-Tend interval in dogs with pacing-induced heart failure. Heart Rhythm 2012; 9: 2044-2050.
20. Piccirillo G, Rossi P, Mitra M, Quaglione R, Dell'Armi A, Di Barba D, et al. Indexes of temporal myocardial repolarization dispersion and sudden cardiac death in heart failure: Any difference? Ann Noninvasive Electrocardiol 2013; 18: 130-139.
21. Magrì D, Sciomer S, Fedele F, Gualdi G, Casciani E, Pugliese P, et al. Increased QT variability in young asymptomatic patients with betathalassemia major. Eur J Haematol 2007; 79: 322-329.
22. Magrì D, Piccirillo G, Bucci E, Pignatelli G, Cauti FM, Morino S, et al. Increased temporal dispersion of myocardial repolarization in myotonic dystrophy type 1: Beyond the cardiac conduction system. Int J Cardiol 2012; 156: 259-264.
23. Autore C, Bernabò P, Barillà CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 2005; 45: 1076-1080.
24. Piccirillo G, Magrì D, Naso C, di Carlo S, Mois EA, De Laurentis T, et al. Factors influencing heart rate variability power spectral analysis during controlled breathing in patients with chronic heart failure or hypertension and in healthy normotensive subjects. Clin Sci (Lond) 2004; 107: 183-190.
25. Piccirillo G, Magnanti M, Matera S, Di Carlo S, De Laurentis T, Torrini A, et al. Age and QT variability index during free breathing, controlled breathing and tilt in patients with chronic heart failure and healthy control subjects. Transl Res 2006; 148: 72-78.
26. Berger RD, Kasper EK, Baughman KL, Marban E, Calkins H, Tomaselli GF. Beat-to-beat QT interval variability: Novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation 1997; 96: 1557-1565.
27. Perkiomaki JS, Koistinen J, Yli-Mlyry S, Huikuri HV. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J Am Coll Cardiol 1995; 26: 174-179.
28. Uchiyama K, Hayashi K, Fujino N, Konno T, Sakamoto Y, Sakata K, et al. Impact of QT variables on clinical outcome of genotyped hypertrophic cardiomyopathy. Ann Noninvasive Electrocardiol 2009; 14: 65-71.
29. Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 2001; 218: 215-223.
30. Kuribayashi T, Roberts WC. Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Am J Cardiol 1992; 70: 1333-1340.
31. Payá E, Marín F, González J, Gimeno JR, Feliu E, Romero A, et al. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: Clinical implications. J Card Fail 2008; 14: 414-419.
32. Motoyasu M, Kurita T, Onishi K, Uemura S, Tanigawa T, Okinaka T, et al. Correlation between late gadolinium enhancement and diastolic function in hypertrophic cardiomyopathy assessed by magnetic resonance imaging. Circ J 2008; 72: 378-383.
33. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010; 56: 875-887.
34. Magrì D, Agostoni P, Cauti FM, Musumeci B, Egidy Assenza G, De Cecco CN, et al. Determinants of peak oxygen uptake in patients with hypertrophic cardiomyopathy: A single-center study. Intern Emerg Med 2012 October 7, doi:10.1007/s11739-012-0866-x.
35. Moon J, Hong YJ, Kim YJ, Shim CY, Jang Y, Chung N, et al. Extent of late gadolinium enhancement on cardiovascular magnetic resonance imaging and its relation to left ventricular longitudinal functional reserve during exercise in patients with hypertrophic cardiomyopathy. Circ J 2013; 77: 1742-1749.
36. Shimizu M, Ino H, Yamaguchi M, Terai H, Hayashi K, Kiyama M, et al. Chronological electrocardiographic changes in patients with hypertrophic cardiomyopathy associated with cardiac troponin I mutation. Am Heart J 2002; 143: 289-293.
37. Sakata K, Shimizu M, Ino H, Yamaguchi M, Terai H, Hayashi K, et al. QT dispersion and left ventricular morphology in patients with hypertrophic cardiomyopathy. Heart 2003; 89: 882-886.
38. Matoh F, Satoh S, Shiraki K, Saitoh T, Urushida T, Katoh H, et al. Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy. J Card Fail 2007; 13: 372-379.
39. Choi DS, Ha JW, Choi B, Yang WI, Choi EY, Rim SJ, et al. Extent of late gadolinium enhancement in cardiovascular magnetic resonance and its relation with left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Circ J 2008; 72: 1449-1453.
40. Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2010; 106: 261-267.
41. Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy ≥60 years of age. Circulation 2013; 127: 585-593.
42. Piccirillo G, Moscucci F, Pascucci M, Pappadà MA, D'Alessandro G, Rossi P, et al. Influence of aging and chronic heart failure on temporal dispersion of myocardial repolarization. Clin Interv Aging 2013; 8: 293-300.
43. Piccirillo G, Raffaele Q, Fimognari F, Moisè A, Mario M, Lionetti M, et al. Influence of L-arginine and vitamin C on the autonomic nervous system in chronic heart failure secondary to ischemic cardiomyopathy. Am J Cardiol 2004; 93: 650-654.
44. Piccirillo G, Magrì D, Di Carlo S, De Laurentis T, Torrini A, Matera S, et al. Influence of cardiac-resynchronization therapy on heart rate and blood pressure variability: 1-year follow-up. Eur J Heart Fail 2006; 8: 716-722.
45. Atiga WL, Fananapazir L, McAreavey D, Calkins H, Berger RD. Temporal repolarization lability in hypertrophic cardiomyopathy caused by beta-myosin heavy-chain gene mutations. Circulation 2000; 101: 1237-1242.
46. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: Clinical perspectives. J Am Coll Cardiol 2012; 60: 705-715.
47. Núñez L, Gimeno-Blanes JR, Rodríguez-García MI, Monserrat L, Zorio E, Coats C, et al. Somatic MYH7, MYBPC3, TPM1, TNNT2 and TNNI3 mutations in sporadic hypertrophic cardiomyopathy. Circ J 2013; 77: 2358-2365.
48. Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations associated with sudden death in hypertrophic cardiomyopathy in the absence of conventional risk factors. Heart Rhythm 2012; 9: 57-63.
49. Efthimiadis GK, Pagourelias ED, Parcharidou D, Gossios T, Kamperidis V, Theofilogiannakos EK, et al. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction. Circ J 2013; 77: 2366-2374.